PPT-New areas of research on the pathophysiology and biomarkers

George L King MD Joslin Diabetes Center Harvard Medical School Type 2 diabetes gt 90 of total gt95 in AA Mostly in adults but increasing in children Not insulin requiring Insulin resistant IR. Leslie M Shaw & John Q . Trojanowski. Magdalena Korecka. Michal Figurski. Teresa . Waligorska. Magdalena Brylska. Leona Fields. Nirali. Shah. Biomarker Core Aims for ADNI 3. Continue to collect, store, curate and track all . James L. Cook, DVM, . PhD. Director, Comparative Orthopaedic Lab & . Mizzou. . BioJoint. Center. cookjl@health.missouri.edu. Osteoarthritis (OA): . Everyone’s Problem. Markets. Canine. 78M companion dogs in US (2015 APPA Survey). Sid E. O’Bryant, Ph.D.. Sid.obryant@unthsc.edu. Blood Based Biomarkers PIA. Founding Goals of the PIA. Standardization & Best Practices for the field. Increasing access to data & virtual repository. Mike Chapman. University of Cambridge Department of Haematology. Novel agents have improved survival. What is a biomarker?. “A characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention”. actively. conducting . translational . medicine. research . to further our . understanding. of . cancer biology and to . identify. which . patient populations may . be. more . likely to derive benefit . Paul Dagum, MD PhD. Mindstrong Health. National Alliance in Mental Health. Washington, CD. June 30, 2017 . CHALLENGES IN MENTAL HEALTH. LACK OF MEASUREMENT. Episodic, subjective measures in laboratory environments lack sensitivity — may fail to detect clinical change . Methods in Clinical Cancer Research. February 12, 2015. Effective incorporation of . biomarkers into phase II trials. There are many roles for biomarkers in Phase II trial designs.. Examples of biomarkers with pivotal role in development of new therapies. Ruturaj R. Masvekar, PhD. Neuroimmunological Diseases Section (NDS). National Institute of Allergy and Infectious Diseases (NIAID). National Institutes of Health (NIH). 1. The efficacy of immunomodulatory treatments in MS decreases with age and disease evolution. a measurable indicator . that . can . tell . us something about a person’s health or disease . state, for example, . disease (pathological) processes in the body, for example, disease stage. , . biological processes in the body (heart rate, blood pressure, temperature), . Presented by: . Dr. Puneet Opal . Dr. Hayley McLoughlin. A Virtual Event. March 17-19, 2022. DISCLAIMER. 2022 AAC. A Virtual Event. March 17-19. PRESENTER DISCLOSURES. Dr. Puneet Opal (Northwestern University). Pragya Kumari. 1. , . Atanu. Bhattacharjee. 2. , Gajendra K. Vishwakarma. 1. 1. Indian Institute of Technology (ISM) Dhanbad, India, 826004. 2. Institute of . Acturial. . Sceience. and Data Analytics, UCSI University, Malaysia, 56000. Leyen. Vu, DO. Sept. 8. th. , 2018. WSU Cougar Health Services. WSU Athletics Team Physician. Objectives. Need for objective measures for concussion. Identify characteristics of ideal serum biomarkers for concussion. ’. s disease. . Mirjana. Babić. 1. , Magdalena . Krbot. Skorić. 2. , Nataša Klepac. 3. , Natalia Palac. 3. , Lea Langer. 4. , . Željka. . Vogrinc. 3. ,. Fran . Borovečki. 3. , Patrick R. Hof. Peter J. Goadsby. King’s College London, UK. University of California, Los Angeles, USA. Migraine and Trigeminal Autonomic Cephalalgias: Pathophysiology, Diagnosis and Management. XXVI World Congress of Neurology.